Novartis East Hanover

Novartis announced another round of job cuts at its US headquarters in East Hanover, New Jersey, eliminating 322 positions effective October 2, 2026, according to a WARN filing. This is the fourth round of reductions at the site in five months and brings the total planned job cuts at the East Hanover campus to 572 for the year. The company said the cuts affect commercial functions — including field sales, patient support and marketing — as it reorganises parts of its commercial business in response to changing market conditions and patent expiries on key medicines. Novartis framed the restructuring as an effort to enhance operational efficiency and realign resources with evolving patient, customer and business needs.

Novartis announced a fourth round of workforce reductions at its East Hanover, New Jersey headquarters, with a WARN filing showing 322 positions to be eliminated effective October 2, 2026. These latest cuts bring the total planned job losses at the site to 572 this year, following earlier rounds that eliminated 114, 76 and 60 roles tied to rare disease sales, biomedical research and US field sales teams. The company said the restructuring affects field sales, patient support and marketing as it reorganises commercial functions in response to changing market conditions and patent expiries on key medicines including Tasigna, Promacta and Entresto. Novartis framed the reductions as efforts to enhance operational efficiency and align resources with evolving patient, customer and business needs as part of a multi-year transformation.

Novartis dismissed 322 staffers based out of its U.S. headquarters, with cuts affecting employees at its East Hanover, New Jersey site. The article reports the company has eliminated these positions as part of workforce reductions centered at its U.S. headquarters. No specific department was named, and the story frames the cuts within broader company restructuring reported by Fierce Pharma. Novartis provided the headcount of 322 affected employees but the article does not give an exact date the dismissals took place or additional timeline details. The layoffs are presented as already executed rather than planned.

Novartis announced a fourth round of cuts at its East Hanover, New Jersey site, letting go of 322 employees effective Oct. 2 per a WARN notice. Those layoffs bring the total number affected at the East Hanover location to 572 after prior rounds in March (114), April (60) and May (76). Overall, Novartis expects to let go of around 800 employees by the end of 2028 and has announced at least 792 job reductions in 2026, including a planned shutdown of a Wehr, Germany production site that will eliminate 220 positions by the end of 2028. The company has also cut workforce in 2025 (1,069 jobs) and said some biomedical research staff were a “select number” laid off in May, while continuing to pursue acquisitions and pipeline investments.

Novartis has laid off 60 workers at its Flatiron biotech division following its $1.4 billion acquisition of the company. This decision reflects the company's strategic adjustments post-acquisition as it integrates Flatiron into its operations. The layoffs are part of a broader effort to streamline the workforce and enhance efficiency within the newly acquired entity. The affected employees were primarily based in New York, where Flatiron's headquarters is located. This move underscores the challenges and changes that often accompany large-scale acquisitions in the biotech industry.

Novartis East Hanover has announced the layoff of 427 employees as part of a strategic restructuring plan aimed at addressing ongoing patent challenges. This decision reflects the company's efforts to streamline operations and adapt to changing market conditions. The layoffs are effective immediately, impacting various roles within the organization. The company has indicated that these changes are necessary to maintain competitiveness and ensure long-term sustainability. This move comes amid broader industry challenges, but Novartis is focusing on its specific operational needs.

Novartis East Hanover has announced layoffs affecting a select number of roles within its biomedical research department as part of a broader reorganization effort. While the exact number of employees impacted has not been disclosed, the decision reflects the company's strategic adjustments in response to evolving market conditions. This move is indicative of Novartis's ongoing efforts to streamline operations and focus on core areas of research and development. The company has not provided specific details regarding the timeline for these layoffs or the future direction of its research initiatives.

Novartis has announced the closure of its manufacturing site in Germany, resulting in the loss of 220 jobs. This decision reflects the company's ongoing restructuring efforts as it adapts to changing market conditions. The layoffs are part of a broader strategy to streamline operations and enhance efficiency within the organization. The affected employees will be notified as the company moves forward with its plans to discontinue operations at this facility. This move underscores Novartis's commitment to optimizing its manufacturing capabilities in response to industry demands.

Novartis East Hanover has laid off 60 employees at its US headquarters, following earlier cuts made in March. This decision is part of the company's ongoing restructuring efforts aimed at streamlining operations. The layoffs reflect the company's response to current market conditions and operational efficiency goals. The affected roles were primarily within the corporate structure, indicating a focus on reducing overhead costs. This move follows a trend of workforce reductions within the pharmaceutical industry as companies adapt to changing economic landscapes.

Novartis has laid off 114 employees at its New Jersey headquarters as part of a continuing restructuring effort. This decision reflects the company's ongoing adjustments to streamline operations and enhance efficiency. The layoffs are part of a broader strategy to optimize resources and align with market demands. The affected positions were not specified, but the cuts are indicative of the company's response to evolving business conditions. Novartis remains committed to its long-term goals while navigating these workforce changes.

Novartis has announced layoffs affecting approximately 300 employees as part of its efforts to streamline operations in the United States. The decision comes amid ongoing restructuring initiatives aimed at enhancing efficiency and reducing costs. The layoffs are expected to take effect on October 1, 2023, as the company seeks to adapt to changing market conditions and improve its operational framework. This move reflects Novartis's commitment to maintaining competitiveness in the pharmaceutical industry while managing its workforce effectively.

Novartis East Hanover has announced layoffs affecting approximately 300 employees at its New Jersey headquarters. The job cuts are part of a broader restructuring effort aimed at streamlining operations and reducing costs. This decision comes amid ongoing challenges in the pharmaceutical industry, including increased competition and pressure to lower drug prices. The layoffs are expected to take effect immediately, impacting various departments within the company. Novartis has stated that these changes are necessary to maintain its competitive edge and ensure long-term sustainability.

Novartis is laying off approximately 300 employees at its New Jersey plant. This decision comes as part of the company's restructuring efforts aimed at optimizing operations and reducing costs. The layoffs are expected to impact various roles within the facility, although specific departments affected have not been disclosed. The company has stated that these changes are necessary to maintain competitiveness in the pharmaceutical industry. The layoffs are part of a broader trend affecting the sector, but Novartis has emphasized its commitment to its remaining workforce and future growth.

Novartis East Hanover has announced the layoff of 427 employees as part of a strategic restructuring plan aimed at addressing ongoing patent challenges. This decision reflects the company's efforts to streamline operations and adapt to the evolving pharmaceutical landscape. The layoffs are expected to impact various roles within the organization, although specific departments affected were not detailed. The company is navigating a difficult market environment, prompting this significant workforce reduction. The layoffs are effective immediately as part of the company's broader strategy to enhance efficiency and focus on core business areas.

Novartis East Hanover has announced plans to cut 250 jobs in New Jersey as part of a broader restructuring effort. The layoffs are part of the company's strategy to streamline operations and reduce costs amid ongoing challenges in the pharmaceutical industry. While specific reasons for the job cuts were not detailed, the company is focusing on enhancing efficiency and adapting to market demands. The layoffs are expected to impact various roles within the organization, although further details on specific departments have not been disclosed.

Novartis has announced plans to cut 114 jobs at its East Hanover headquarters. This decision is part of a broader restructuring effort aimed at streamlining operations and reducing costs. The layoffs are expected to impact various roles within the organization, although specific departments have not been disclosed. The company has not provided a timeline for when these job cuts will take effect. This move reflects ongoing challenges in the pharmaceutical industry as companies adapt to changing market conditions.

Novartis East Hanover has announced plans to lay off over 400 workers at its New Jersey facility. The layoffs are part of a restructuring effort aimed at streamlining operations and reducing costs. While specific dates for the layoffs have not been disclosed, the company is preparing for significant workforce reductions. This decision reflects broader challenges within the pharmaceutical industry as companies adapt to changing market conditions. The layoffs will impact various roles within the organization, although detailed departmental information has not been provided.

Novartis East Hanover has announced plans to lay off 58 employees in New Jersey as part of its ongoing efficiency drive. This decision reflects the company's efforts to streamline operations and reduce costs. The layoffs are part of a broader strategy to enhance productivity within the organization. Specific details regarding the departments affected have not been disclosed. The company aims to implement these changes to better align with its operational goals and market demands.

Novartis is planning job cuts at its Belgian site as part of a restructuring initiative. The company has not specified the exact number of positions that will be affected, but the restructuring is part of a broader strategy to streamline operations. This move reflects the company's ongoing efforts to adapt to changing market conditions and improve efficiency. Further details regarding the timeline and specific departments impacted have yet to be announced.

Novartis has announced plans to cut up to 550 jobs at its facility in Switzerland. This decision reflects the company's ongoing efforts to streamline operations and adapt to changing market conditions. The layoffs are part of a broader strategy to enhance efficiency and reduce costs. While specific dates for the layoffs have not been disclosed, the company is preparing for these changes in the near future. This move underscores the challenges faced by Novartis in maintaining competitiveness in the pharmaceutical industry.